Aurobindo Pharma declares Rs 7 interim dividend; record date Nov 11

The Board of Directors has approved the payment of interim dividend of 700% i.e. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each on the equity share capital of the Company.

As per item (b) in the board's outcome letter, the company has also specified the key dates for determining eligibility and making the payment.

• Type of corporate action: Interim dividend
• Dividend rate: "700% i.e. Rs.7.00 (Rupees seven only) per equity share of Re.1/- each"
• Face value of shares: "Re.1/- each"
• Record date: "November 11, 2026"
• Payment date / timeline: "on or before November 20, 2026"

According to the board's outcome letter, "The Company has fixed November 11, 2026, as the Record Date for the purpose of payment of Interim Dividend".

In practical terms:

• Investors whose names appear as shareholders in the company’s records as of November 11, 2026 will be eligible to receive the interim dividend of Rs.7.00 per equity share of Re.1/- each.
• The stock exchanges will separately specify the ex-dividend date based on this record date; investors typically need to own the shares before the ex-dividend date for their holdings to be reflected on the record date. (The ex-date itself is not stated in the filing.)

The same communication states that the interim dividend "will be paid on or before November 20, 2026". This is the outer limit by which eligible shareholders can expect the dividend to be credited or paid, depending on their registered mode (electronic transfer or physical warrant, as per their records with the company/registrar).

The interim dividend decision is part of a wider set of approvals taken at the Board Meeting held on November 4, 2026, as listed in the outcome letter:

• Approval of the standalone and consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026, along with the limited review reports.
• A proposal to file a Scheme of Amalgamation for merger of Auroactive Pharma Private Limited, a wholly owned subsidiary, with Apitoria Pharma Private Limited, also a wholly owned subsidiary, with the Hon’ble NCLT, Hyderabad.
• Approval of the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, both wholly owned subsidiaries.
• Based on the recommendation of the Nomination and Remuneration/Compensation Committee and subject to the approval of the Members through Postal Ballot, the re-appointment of Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) as a Director (Non-executive and Independent) for a second term of 5 (five) years with effect from April 1, 2027.

The company has not provided a separate narrative rationale for the interim dividend within the outcome letter; it is presented as one of the decisions approved at the meeting.

The board meeting, as disclosed, "commenced at 4:15 p.m. and concluded at 6:00 p.m." on November 4, 2026.